UroGen Stock Up 49% on Full Enrollment for Bladder Cancer Study
July 27 2023 - 11:06AM
Dow Jones News
By Sabela Ojea
Shares of UroGen Pharma surged on Thursday after the
biotechnology company said Phase 3 trials for its bladder cancer
investigational treatment UGN-102 are fully enrolled.
The stock was up 49% to $13.37 at 11:18 a.m. ET. The shares have
jumped 62% in the past 12 months.
The company said completing enrollment for the study is a major
milestone that brings them one step closer validation of the
medication for low-grade intermediate-risk nonmuscle-invasive
bladder cancer.
UroGen expects to submit a New Drug Application with the Food
and Drug Administration for the treatment UGN-102 in 2024.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
July 27, 2023 11:51 ET (15:51 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
UroGen Pharma (NASDAQ:URGN)
Historical Stock Chart
From May 2024 to Jun 2024
UroGen Pharma (NASDAQ:URGN)
Historical Stock Chart
From Jun 2023 to Jun 2024
